ARID1A and ovarian cancer: This demonstrates that even very frequent and potential cancer driving mutations such as PTEN and ARID1A in endometrioid endometrial and ovarian cancer may not be found in distant metastases, a fact that is essential for potential future targeted therapies [17–19].